Introductory rifampicin therapy in lepromatous leprosy: a six month follow-up study.
A double-blind comparative trial of 300 mg of Rifampicin given daily as against 50 mg D.D.S. administered likewise for an initial period of 3 months has been undertaken on 24 untreated cases of lepromatous leprosy. All the patients have been followed up for 6 months. The results revealed that patients in the former group became non-infective, as concluded from M.I. and mouse foot-pad results, within 3-4 weeks and their nasal ulcers healed faster. Clinical improvement was slightly better in the former group while no bacteriological differences were noticed in the two groups. E.N.L. was milder and slightly less common in the Rifampicin group.
D002986:Clinical Trials as Topic; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D007918:Leprosy / Q000188:drug therapy*; D008297:Male; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*
D003622:Dapsone; D012293:Rifampin